

RFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Euykerman et al.

Serial No.: 10/751,072

Filed: January 2, 2004

For: REVERSED MAMMALIAN  
PROTEIN-PROTEIN INTERACTION TRAP

Confirmation No.: 2266

Group Art Unit: 1645

Attorney Docket No.: 2676-6264US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 22, 2004  
Date

  
Signature

Betty Vowles  
Name (Type/Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are not being submitted pursuant to Pre-OG Notices <<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/idswouscopies.htm>> (visited 9/15/2003). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Serial No.: 10/751,072

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,525,490	06-11-1996	Erickson et al.
US - 5,637,463	06-10-1997	Dalton et al.
US - 5,733,726	03-31-1998	Fu et al.
US - 6,303,319 B1	10-16-2001	Rickles
US - 6,479,280 B1	11-12-2002	Muyldermans et al.
US - 2002/0019006 A1	02-14-2002	Yuan et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
FR 2 782 084 A1	02-11-2000	Centre National de la Recherche Scientifique CNRS
EP 1 088 892 A1	04-04-2001	Vlaams Interuniversitair Instituut voor Biotechnologie VZW
WO 90/02809	03-22-1990	Protein Engineering Corporation
WO 92/20791	11-26-1992	Cambridge Antibody Technology Limited
WO 95/26400	10-05-1995	Onyx Pharmaceuticals, Inc.
WO 97/10330	03-20-1997	Bioinvent International AB
WO 97/31113	08-28-1997	Ariad Pharmaceuticals, Inc.
WO 97/32017	09-04-1997	Morphosys Gesellschaft fur Proteinoptimierung MBH
WO 98/13502	04-02-1998	ICOS Corporation
WO 99/66324	12-23-1999	Joly et al.
WO 00/46406	08-10-2000	Alphagene, Inc.

Serial No.: 10/751,072

WO 00/07014	02-10-2000	Vlaams Interuniversitair Instituut voor Biotechnologie VZW
WO 00/08148	02-17-2000	Association Pour le Develooppement de l'immunologie Moleculaire Vlaams Interuniversitair
WO 03/004643 A2	01-16-2003	Instituut voor Biotechnologie VZW

Other Documents

EYCKERMAN et al., Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor, FEBS Letters, 2000, pp. 33-37, Vol. 486.

FASHENA et al., The continued evolution of two-hybrid screening approaches in yeast: how to outwit different preys with different baits, Gene, 2000, pp. 1-14, Vol. 250.

LI et al., Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction, Proc. Natl. Acad. Sci., August 1999, pp. 9677-82, Vol. 96, USA.

OSBORNE et al., The Yeast Tribid System--Genetic Detection of trans-phosphorylated ITAM-SH2-Interactions, Bio/technology, December 1995, pp 1474-78, Vol. 13.

PCT International Search Report, PCT/EP02/07419, dated December 20, 2002.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2676-4644US  
Serial No.: 09/771,425  
Filing Date: 1/26/2001  
Title: EUKARYOTIC CELL-BASED INTERACTION CLONING

Serial No.: 10/751,072

Attorney Docket No.: 2676-4651.1US  
Serial No.: 10/235,264  
Filing Date: 9/4/2002  
Title: LEPTIN-MEDIATED GENE-INDUCTION

Attorney Docket No.: 2676-5563US  
Serial No.: 10/303,157  
Filing Date: 11/22/2002  
Title: RECEPTOR-BASED INTERACTION TRAP

Attorney Docket No.: 2676-5579US  
Serial No.: 10/310,304  
Filing Date: 12/5/2002  
Title: METHOD TO INDUCE THE TH1 IMMUNE RESPONSE

Attorney Docket No.: 2676-4614.1US  
Serial No.: 10/415,781  
Filing Date: 9/22/2003  
Title: FUNCTIONAL FRAGMENT OF THE LEPTIN RECEPTOR

Attorney Docket No.: 2676-6264US  
Serial No.: 10/751,072  
Filing Date: 1/2/2004  
Title: REVERSED MAMMALIAN PROTEIN-PROTEIN INTERACTION TRAP

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,




Allen C. Turner  
Registration No. 33,041  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: June 21, 2004

ACT/bv

Enclosures: Form PTO/SB/08 and Cited Documents

Document in ProLaw



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for Trademark PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/751,072
		Filing Date	January 2, 2004
		First Named Inventor	Euykerman et al.
		Group Art Unit	1645
		Examiner Name	To be assigned
Sheet 1 of 2	Attorney Docket Number	2676-6264US	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-5,525,490	06-11-1996	Erickson et al.	
		US- 5,637,463	06-10-1997	Dalton et al.	
		US- 5,733,726	03-31-1998	Fu et al.	
		US- 6,303,319 B1	10-16-2001	Rickles	
		US- 6,479,280 B1	14-12-2002	Muyldermans et al.	
		US- 2002/0019006 A1	02-14-2002	Yuan et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		FR 2 782 084 A1	02-11-2000	Centre National de la Recherche Scientifique CNRS		
		EP 1 088 892 A1	04-04-2001	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		
		WO 90/02809	03-22-1990	Protein Engineering Corporation		
		WO 92/20791	11-26-1992	Cambridge Antibody Technology Limited		
		WO 95/26400	10-05-1995	Onyx Pharmaceuticals, Inc.		
		WO 97/10330	03-20-1997	Bioinvent International AB		
		WO 97/31113	08-28-1997	Ariad Pharmaceuticals, Inc.		
		WO 97/32017	09-04-1997	Morphosys Gesellschaft fur Proteinoptimierung MBH		
		WO 98/13502	04-02-1998	ICOS Corporation		
		WO 99/66324	12-23-1999	Joly et al.		
		WO 00/46406	08-10-2000	Alphagene, Inc.		
		WO 00/07014	02-10-2000	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		
		WO 00/08148	02-17-2000	Association Pour le Developpement de l'immunologie Moleculaire		
		WO 03/004643 A2	01-16-2003	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Information Disclosure Statement

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/751,072
Filing Date	January 2, 2004
First Named Inventor	Euykerman et al.
Group Art Unit	1645
Examiner Name	To be assigned
Attorney Docket Number	2676-62641US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		EYCKERMAN et al., Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor, FEBS Letters, 2000, pp. 33-37, Vol. 486.	
		FASHENA et al., The continued evolution of two-hybrid screening approaches in yeast: how to outwit different preys with different baits, Gene, 2000, pp. 1-14, Vol. 250.	
		LI et al., Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction, Proc. Natl. Acad. Sci., August 1999, pp. 9677-82, Vol. 96, USA.	
		OSBORNE et al., The Yeast Tribid System—Genetic Detection of trans-phosphorylated ITAM-SH2-Interactions, Bio/technology, December 1995, pp 1474-78, Vol. 13.	
		PCT International Search Report, PCT/EP02/07419, dated December 20, 2002.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.